Systematic Evidence-Based Analysis of Plaque Injection Therapy for Peyronie's Disease

European Urology

Volumn 51, Issue 3, 2007, Pages 640-647

  Russell, Shane ^a   Steers, William ^b   McVary, Kevin T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Erectile dysfunction; Injection therapy; Peyronie's disease

Indexed keywords

ALPHA2B INTERFERON; COLLAGENASE; CORTICOSTEROID; PLACEBO; VERAPAMIL;

CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; ERECTILE DYSFUNCTION; EVALUATION; EVIDENCE BASED MEDICINE; HUMAN; MALE; MEDICAL LITERATURE; META ANALYSIS; OUTCOME ASSESSMENT; PEER REVIEW; PEYRONIE DISEASE; PRIORITY JOURNAL; RATING SCALE; REVIEW; SYSTEMATIC REVIEW;

ADRENAL CORTEX HORMONES; COLLAGENASES; EVIDENCE-BASED MEDICINE; HUMANS; INJECTIONS, INTRALESIONAL; INTERFERONS; MALE; PENILE INDURATION; VERAPAMIL;

EID: 33846237744     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.10.042     Document Type: Review

References (57)

1. Hamilton R.G., Mintz G.R., and Gelbard M.K. Humoral immune responses in Peyronie's disease patients receiving clostridial collagenase therapy. J Urol 135 (1986) 641-647
2. Rehman J., Benet A., and Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology 51 (1998) 620-626
3. Sommer F., Schwarzer U., Wassmer G., et al. Epidemiology of Peyronie's disease. Int J Impot Res 14 (2002) 379-383
4. Moreland R.B., and Nehra A. Pathophysiology of Peyronie's disease. Int J Impot Res 14 (2002) 406-410
5. Vande Berg J.S., Devine Jr. C.J., Horton C.E., et al. Mechanisms of calcification in Peyronie's disease. J Urol 127 (1982) 52-54
6. Hirano D., Takimoto Y., Yamamoto T., Hirakata H., and Kawata N. Electron microscopic study of the penile plaques and adjacent corpora cavernosa in Peyronie's disease. Int J Urol 4 (1997) 274-278
7. Mulhall J.P. Expanding the paradigm for plaque development in Peyronie's disease. Int J Impot Res 15 suppl 5 (2003) S93-S102
8. Pryor J.P., and Ralph D.J. Clinical presentations of Peyronie's disease. Int J Impot Res 14 (2002) 414-417
9. Lopez J.A., and Jarow J.P. Penile vascular evaluation of men with Peyronie's disease. J Urol 149 (1993) 53-55
10. Akkus E., Carrier S., Baba K., et al. Structural alterations in the tunica albuginea of the penis: impact of Peyronie's disease, ageing and impotence. Br J Urol 79 (1997) 47-53
11. Teloken C., Rhoden E.L., Grazziotin T.M., Ros C.T., Sogari P.R., and Souto C.A. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 162 (1999) 2003-2005
12. Biagiotti G., and Cavallini G. Acetyl-l-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int 88 (2001) 63-67
13. Martin D.J., Badwan K., Parker M., and Mulhall J.P. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 168 (2002) 2483-2485
14. Levine L.A., Estrada C.R., Shou W., and Cole A. Tunica albuginea tissue analysis after electromotive drug administration. J Urol 169 (2003) 1775-1778
15. Carson III C.C., and Coughlin P.W. Radiation therapy for Peyronie's disease: is there a place?. J Urol 134 (1985) 684-686
16. Hauck E.W., Altinkilic B.M., Ludwig M., et al. Extracorporal shock wave therapy in the treatment of Peyronie's disease. First results of a case-controlled approach. Eur Urol 38 (2000) 663-669 discussion 670
17. Kim E.D., and McVary K.T. Long-term followup of treatment of Peyronie's disease with plaque incision, carbon dioxide laser plaque ablation and placement of a deep dorsal vein patch graft. J Urol 153 (1995) 1843-1846
18. Hellstrom W.J., and Usta M.F. Surgical approaches for advanced Peyronie's disease patients. Int J Impot Res 15 suppl 5 (2003) S121-S124
19. Mynderse L.A., and Monga M. Oral therapy for Peyronie's disease. Int J Impot Res 14 (2002) 340-344
20. Gelbard M.K., James K., Riach P., and Dorey F. Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol 149 (1993) 56-58
21. Levine L.A. Treatment of Peyronie's disease with intralesional verapamil injection. J Urol 158 (1997) 1395-1399
22. Levine L.A., Goldman K.E., and Greenfield J.M. Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 168 (2002) 621-625 discussion 625-6
23. Levine L.A., and Greenfield J.M. Establishing a standardized evaluation of the man with Peyronie's disease. Int J Impot Res 15 suppl 5 (2003) S103-S112
24. Hellstrom W.J., Kendirci M., Matern R., et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 176 (2006) 394-398
25. Gelbard M.K., Dorey F., and James K. The natural history of Peyronie's disease. J Urol 144 (1990) 1376-1379
26. Williams J.L., and Thomas G.G. The natural history of Peyronie's disease. J Urol 103 (1970) 75-76
27. Kadioglu A., Akman T., Sanli O., Gurkan L., Cakan M., and Celtik M. Surgical treatment of Peyronie's disease: a critical analysis. Eur Urol 50 (2006) 235-248
28. Padma-Nathan H., Christ G., Adaikan G., Becher E., Brock G., and Carrier S. Pharmacotherapy for erectile dysfunction. In: Lue T.F., Basson R., Rosen R., Giulian F., Khoury S., and Montorsi F. (Eds). Second international consultation on sexual dysfunction, 2004 (2004), International Consultation on Urological Diseases (ICUD), International Society of Urology (SIU), and International Society for Sexual and Impotence Research (ISSIR), Paris 503-565
29. Bodner H., Howard A.H., and Kaplan J.H. Peyronie's disease; cortisone - hyaluronidase - hydrocortisone therapy. Trans West Sect Am Urol Assoc 20 (1953) 32-35
30. Mirone V., Imbimbo C., Palmieri A., and Fusco F. Our experience on the association of a new physical and medical therapy in patients suffering from induratio penis plastica. Eur Urol 36 (1999) 327-330
31. Lamprakopoulos A., Zorzos I., and Lykourinas M. The use of betamethasone and hyaluronidase injections in the treatment of Peyronie's disease. Scand J Urol Nephrol 34 (2000) 355-360
32. Cavallini G., Biagiotti G., Koverech A., and Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int 89 (2002) 895-900
33. Levine L.A. Review of current nonsurgical management of Peyronie's disease. Int J Impot Res 15 suppl 5 (2003) S113-S120
34. Gelbard M.K., Lindner A., and Kaufman J.J. The use of collagenase in the treatment of Peyronie's disease. J Urol 134 (1985) 280-283
35. Dietrich J.W., and Duffield R. Effects of the calcium antagonist verapamil on in vitro synthesis of skeletal collagen and noncollagen protein. Endocrinology 105 (1979) 1168-1172
36. 2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA 93 (1996) 5478-5482
37. Lee R.C., and Ping J.A. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res 49 (1990) 463-466
38. Steinleitner A., Kazensky C., and Lambert H. Calcium channel blockade prevents postsurgical reformation of adnexal adhesions in rabbits. Obstet Gynecol 74 (1989) 796-798
39. Lee R.C., Doong H., and Jellema A.F. The response of burn scars to intralesional verapamil. Report of five cases. Arch Surg 129 (1994) 107-111
40. Lacy II G.L., Adams D.M., and Hellstrom W.J. Intralesional interferon-alpha-2b for the treatment of Peyronie's disease. Int J Impot Res 14 (2002) 336-339
41. Duncan M.R., Berman B., and Nseyo U.O. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 25 (1991) 89-94
42. Larrabee Jr. W.F., East C.A., Jaffe H.S., Stephenson C., and Peterson K.E. Intralesional interferon gamma treatment for keloids and hypertrophic scars. Arch Otolaryngol Head Neck Surg 116 (1990) 1159-1162
43. Haag S.M., Hauck E.W., Szardening-Kirchner C., et al. Alterations in the transforming growth factor (TGF)-β pathway as a potential factor in the pathogenesis of Peyronie's disease. Eur Urol 51 (2007) 255-261
44. Hauck E.W., Diemer T., Schmelz H.U., and Weidner W. A critical analysis of nonsurgical treatment of Peyronie's disease. Eur Urol 49 (2006) 987-997
45. Winter C.C., and Khanna R. Peyronie's disease: results with dermo-jet injection of dexamethasone. J Urol 114 (1975) 898-900
46. Desanctis P.N., and Furey Jr. C.A. Steroid injection therapy for Peyronie's disease: a 10-year summary and review of 38 cases. J Urol 97 (1967) 114-116
47. Teasley G.H. Peyronie's disease; a new approach. J Urol 71 (1954) 611-614
48. Williams G., and Green N.A. The non-surgical treatment of Peyronie's disease. Br J Urol 52 (1980) 392-395
49. Toksu E. Peyronie's disease: a method of treatment. J Urol 105 (1971) 523-524
50. Furey Jr. C.A. Peyronie's disease: treatment by the local injection of meticortelone and hydrocortisone. J Urol 77 (1957) 251-266
51. Levine L.A., Merrick P.F., and Lee R.C. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 151 (1994) 1522-1524
52. Brake M., Loertzer H., Horsch R., and Keller H. Treatment of Peyronie's disease with local interferon-alpha 2b. BJU Int 87 (2001) 654-657
53. Ahuja S., Bivalacqua T.J., Case J., Vincent M., Sikka S.C., and Hellstrom W.J. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease. J Androl 20 (1999) 444-448
54. Wegner H.E., Andresen R., Knipsel H.H., and Miller K. Treatment of Peyronie's disease with local interferon-alpha 2b. Eur Urol 28 (1995) 236-240
55. Wegner H.E., Andresen R., Knispel H.H., and Miller K. Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie's disease. Eur Urol 32 (1997) 190-193
56. Judge I.S., and Wisniewski Z.S. Intralesional interferon in the treatment of Peyronie's disease: a pilot study. Br J Urol 79 (1997) 40-42
57. Polat O., Gul O., Ozbey I., Ozdikici M., and Bayraktar Y. Peyronie's disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging. Int Urol Nephrol 29 (1997) 465-471